Pfizer is in phase three of testing the safety and efficacy of the Lyme disease vaccine.

Researchers are seeking volunteers in the US and Europe to test the first potential vaccine against Lyme disease in 20 years. While the illness has been historically undercounted, the US CDC reports that nearly 476,000 people are treated each year.